Search

Your search keyword '"Glaser, Anna"' showing total 317 results
Start Over Author "Glaser, Anna"
317 results on '"Glaser, Anna"'

1. Big Multiple Sclerosis Data network: an international registry research network

Author

Glaser, Anna, Butzkueven, Helmut, van der Walt, Anneke, Gray, Orla, Spelman, Tim, Zhu, Chao, Trojano, Maria, Iaffaldano, Pietro, Battaglia, Mario A., Lucisano, Giuseppe, Vukusic, Sandra, Vukusic, Irena, Casey, Romain, Horakova, Dana, Drahota, Jiri, Magyari, Melinda, Joensen, Hanna, Pontieri, Luigi, Elberling, Frederik, Klyve, Pernilla, Mouresan, Elena Flavia, Forsberg, Lars, and Hillert, Jan

Published
2024
Full Text
View/download PDF

2. The role of neutrophils in autoimmune disease

Author

Glaser, Anna Elisa Andrea, Beresford, Michael, Midgley, Angela, Peak, Matthew, and Wright, Helen

Subjects
610
Abstract

Background: Juvenile-onset systemic lupus erythematosus (JSLE) is a multisystem autoimmune disease with manifestations being very diverse between individuals. Neutrophils (PMN), the main innate phagocytic cells have been implied to contribute to disease development and show an Interferoninduced gene signatures (IGS) in patients. Contribution of PMN to disease development and patient stratification have mainly been investigated with genomic, transcriptomic, proteomic approaches. Aims: (1) To explore the ability to stratify patients with autoimmune diseases based on their IGS, including a metabolomics approach using urine and serum. (2) To investigate the phagocytosis-related gene (PRG) signature (PGS) and IGS in PMN of JSLE and healthy paediatric controls. (3) To determine if the PGS is translated onto protein and functional level in PMN of JSLE patients. (4) To determine the influence of factors present in the neutrophil environment including Tumour Necrosis Factor (TNF) α, Interferon (IFN) α, nucleosomes and signal released from apoptosing cells, on the PRG signature. Methods: Metabolite profiles of serum and urine were obtained from JSLE patients, Juvenile Idiopathic Arthritis (JIA) and paediatric controls using 1H NMR spectroscopy, bucket tables for serum samples were created with TopSpin® and Chenomx Profiler® whereas urine sample metabolites were annotated and quantified in Chenomx Profiler® for each sample individually. JSLE and paediatric controls were tested for differences in IGS and PGS using real-time PCR, flow cytometry and ELISA. Effects of stimulation with apoptotic supernatant, nucleosomes, IFNα and TNFα on IGS and PGS were also investigated. Phagocytosis was measured using pHrodo coated bioparticles (S.aureus, E.coli, zymosan) with flow cytometry and confocal microscopy. Results: JSLE, JIA and paediatric control patients and the JSLE IFN subgroups were distinguishable from each other in a model with partial-least squares discriminant analysis. Urine metabolites built better models than metabolites of serum. Pathway analysis suggested increased inflammation in patients despite low disease activity and differences for metabolites involved in phagocytosis. The PGS genes TLR2 and S100A9 had increased mRNA and protein expression in neutrophils of JSLE patients compared to paediatric control patients. The main difference between JSLE IFN high and IFN low patients was in FcγRIIIb, which was only high in IFN high patients. Increased PRG expression was reflected in increased phagocytosis of E.coli and zymosan particles. All stimulants tested contributed to the PGS and IGS, in particular the nucleosomes which increased IFNa, IGS expression and triggered S100A8/A9 release. Conclusions: Factors in the neutrophil cell environment of JSLE patients can contribute to increased expression of the PGS and IGS. Differences between JSLE, JSLE IFN high, JSLE IFN low and paediatric control patients can be measured at the mRNA, protein and metabolite level. Strong differences suggest that IFN high and IFN low patient subgroups may have different aetiopathogenesis and different cytokine profiles.

Published
2019
Full Text
View/download PDF

4. Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis

Author

Simpson-Yap, Steve, De Brouwer, Edward, Kalincik, Tomas, Rijke, Nick, Hillert, Jan A, Walton, Clare, Edan, Gilles, Moreau, Yves, Spelman, Tim, Geys, Lotte, Parciak, Tina, Gautrais, Clement, Lazovski, Nikola, Pirmani, Ashkan, Ardeshirdavanai, Amin, Forsberg, Lars, Glaser, Anna, McBurney, Robert, Schmidt, Hollie, Bergmann, Arnfin B, Braune, Stefan, Stahmann, Alexander, Middleton, Rodden, Salter, Amber, Fox, Robert J., van der Walt, Anneke, Butzkueven, Helmut, Alroughani, Raed, Ozakbas, Serkan, Rojas, Juan I, van der Mei, Ingrid, Nag, Nupur, Ivanov, Rumen, Sciascia do Olival, Guilherme, Dias, Alice Estavo, Magyari, Melinda, Brum, Doralina, Mendes, Maria Fernanda, Alonso, Ricardo N, Nicholas, Richard S, Bauer, Johana, Chertcoff, Aníbal Sebastián, Zabalza, Anna, Arrambide, Georgina, Fidao, Alex, Comi, Giancarlo, and Peeters, Liesbet

Published
2021
Full Text
View/download PDF

9. Organizing Commons in Time and Space with Framapads: Feedback from an Open Community

Author

Berkowitz, Héloïse, Brakel, Fiza, Bussy-Socrate, Hélène, Carton, Sabine, Glaser, Anna, Irrmann, Olivier, Taskin, Laurent, Ungureanu, Paula, Vaujany, François-Xavier De, Laboratoire d'Economie et de Sociologie du Travail (LEST), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Aix Marseille Université (AMU), Paris School of Business (PSB), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM), Grenoble Institut d'Administration des Entreprises (UGA INP IAE), Université Grenoble Alpes (UGA)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP ), Université Grenoble Alpes (UGA), Université Catholique de Louvain = Catholic University of Louvain (UCL), Università degli Studi di Modena e Reggio Emilia = University of Modena and Reggio Emilia (UNIMORE), Dauphine Recherches en Management (DRM), Université Paris Dauphine-PSL, and Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)

Subjects
openness, narrative commons, commons, codocumentation, [SHS.GESTION]Humanities and Social Sciences/Business administration, organizationality of commons, Framapad
Abstract

International audience; Commons are also a narrative issue, something collectively told and shared. In this discussion paper, we critically examine our use of a collaborative technique called Framapad. As an open community, RGCS has used hundreds of pads to co-document its events and practices. !is practice, both when successful and unsuccessful, has been key in the constitution of our own commons. Here, we analyze the process, contributions and limitations of pads in the life of our community.

Published
2023

13. Long-term Survival in Multiple Sclerosis is Improving (P5-3.011)

Author

Wergeland, Stig, primary, Mannseth, Janne, additional, Atula, Sari, additional, Forsberg, Lars, additional, Glaser, Anna, additional, Joensen, Hanna, additional, Magyari, Melinda, additional, Soilu-Hanninen, Merja, additional, Viitala, Matias, additional, Hillert, Jan, additional, and Grytten, Nina, additional

Published
2023
Full Text
View/download PDF

14. Proportion and characteristics of secondary progressive multiple sclerosis in five European registries using objective classifiers

Author

Forsberg, Lars, Spelman, Tim, Klyve, Pernilla, Manouchehrinia, Ali, Ramanujam, Ryan, Mouresan, Elena, Drahota, Jiri, Horakova, Dana, Joensen, Hanna, Pontieri, Luigi, Magyari, Melinda, Ellenberger, David, Stahmann, Alexander, Rodgers, Jeff, Witts, James, Middleton, Rod, Nicholas, Richard, Bezlyak, Vladimir, Adlard, Nicholas, Hach, Thomas, Lines, Carol, Vukusic, Sandra, Soilu-Hanninen, Merja, van der Walt, Anneke, Butzkueven, Helmut, Iaffaldano, Pietro, Trojano, Maria, Glaser, Anna, Hillert, Jan, Forsberg, Lars, Spelman, Tim, Klyve, Pernilla, Manouchehrinia, Ali, Ramanujam, Ryan, Mouresan, Elena, Drahota, Jiri, Horakova, Dana, Joensen, Hanna, Pontieri, Luigi, Magyari, Melinda, Ellenberger, David, Stahmann, Alexander, Rodgers, Jeff, Witts, James, Middleton, Rod, Nicholas, Richard, Bezlyak, Vladimir, Adlard, Nicholas, Hach, Thomas, Lines, Carol, Vukusic, Sandra, Soilu-Hanninen, Merja, van der Walt, Anneke, Butzkueven, Helmut, Iaffaldano, Pietro, Trojano, Maria, Glaser, Anna, and Hillert, Jan

Abstract

BackgroundTo assign a course of secondary progressive multiple sclerosis (MS) (SPMS) may be difficult and the proportion of persons with SPMS varies between reports. An objective method for disease course classification may give a better estimation of the relative proportions of relapsing-remitting MS (RRMS) and SPMS and may identify situations where SPMS is under reported. Materials and methodsData were obtained for 61,900 MS patients from MS registries in the Czech Republic, Denmark, Germany, Sweden, and the United Kingdom (UK), including date of birth, sex, SP conversion year, visits with an Expanded Disability Status Scale (EDSS) score, MS onset and diagnosis date, relapses, and disease-modifying treatment (DMT) use. We included RRMS or SPMS patients with at least one visit between January 2017 and December 2019 if >= 18 years of age. We applied three objective methods: A set of SPMS clinical trial inclusion criteria ("EXPAND criteria") modified for a real-world evidence setting, a modified version of the MSBase algorithm, and a decision tree-based algorithm recently published. ResultsThe clinically assigned proportion of SPMS varied from 8.7% (Czechia) to 34.3% (UK). Objective classifiers estimated the proportion of SPMS from 15.1% (Germany by the EXPAND criteria) to 58.0% (UK by the decision tree method). Due to different requirements of number of EDSS scores, classifiers varied in the proportion they were able to classify; from 18% (UK by the MSBase algorithm) to 100% (the decision tree algorithm for all registries). Objectively classified SPMS patients were older, converted to SPMS later, had higher EDSS at index date and higher EDSS at conversion. More objectively classified SPMS were on DMTs compared to the clinically assigned. ConclusionSPMS appears to be systematically underdiagnosed in MS registries. Reclassified patients were more commonly on DMTs., QC 20230320

Published
2023
Full Text
View/download PDF

15. The impact of healthcare systems on the clinical diagnosis and disease-modifying treatment usage in relapse-onset multiple sclerosis: a real-world perspective in five registries across Europe.

Author

Nicholas, Richard, Rodgers, Jeff, Witts, James, Lerede, Annalaura, Friede, Tim, Hillert, Jan, Forsberg, Lars, Glaser, Anna, Manouchehrinia, Ali, Ramanujam, Ryan, Spelman, Tim, Klyve, Pernilla, Drahota, Jiri, Horakova, Dana, Joensen, Hanna, Pontieri, Luigi, Magyari, Melinda, Ellenberger, David, Stahmann, Alexander, and Butzkueven, Helmut

Subjects
MULTIPLE sclerosis, DISEASE progression, META-analysis, BIG data, MEDICAL audit, DECISION trees
Abstract

Introduction: Prescribing guidance for disease-modifying treatment (DMT) in multiple sclerosis (MS) is centred on a clinical diagnosis of relapsing–remitting MS (RRMS). DMT prescription guidelines and monitoring vary across countries. Standardising the approach to diagnosis of disease course, for example, assigning RRMS or secondary progressive MS (SPMS) diagnoses, allows examination of the impact of health system characteristics on the stated clinical diagnosis and treatment access. Methods: We analysed registry data from six cohorts in five countries (Czech Republic, Denmark, Germany, Sweden and United Kingdom) on patients with an initial diagnosis of RRMS. We standardised our approach utilising a pre-existing algorithm (DecisionTree, DT) to determine patient diagnoses of RRMS or secondary progressive MS (SPMS). We identified five global drivers of DMT prescribing: Provision, Availability, Funding, Monitoring and Audit, data were analysed against these concepts using meta-analysis and univariate meta-regression. Results: In 64,235 patients, we found variations in DMT use between countries, with higher usage in RRMS and lower usage in SPMS, with correspondingly lower usage in the UK compared to other registers. Factors such as female gender (p = 0.041), increasing disability via Expanded Disability Status Scale (EDSS) score (p = 0.004), and the presence of monitoring (p = 0.029) in SPMS influenced the likelihood of receiving DMTs. Standardising the diagnosis revealed differences in reclassification rates from clinical RRMS to DT-SPMS, with Sweden having the lowest rate Sweden (Sweden 0.009, range: Denmark 0.103 – UK portal 0.311). Those with higher EDSS at index (p < 0.03) and female gender (p < 0.049) were more likely to be reclassified from RRMS to DT-SPMS. The study also explored the impact of diagnosis on DMT usage in clinical SPMS, finding that the prescribing environment and auditing practices affected access to treatment. Discussion: This highlights the importance of a healthcare system's approach to verifying the clinical label of MS course in facilitating appropriate prescribing, with some flexibility allowed in uncertain cases to ensure continued access to treatment. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

16. Trajectories of disease-modifying therapies and associated sickness absence and disability pension among 1923 people with multiple sclerosis in Sweden

Author

Teni, Fitsum Sebsibe, primary, Machado, Alejandra, additional, Murley, Chantelle, additional, He, Anna, additional, Fink, Katharina, additional, Gyllensten, Hanna, additional, Glaser, Anna, additional, Alexanderson, Kristina, additional, Hillert, Jan, additional, and Friberg, Emilie, additional

Published
2023
Full Text
View/download PDF

17. sj-docx-1-msj-10.1177_13524585231181578 – Supplemental material for Association between clinic-level quality of care and patient-level outcomes in multiple sclerosis

Author

He, Anna H, Manouchehrinia, Ali, Glaser, Anna, Ciccarelli, Olga, Butzkueven, Helmut, Hillert, Jan, and McKay, Kyla Anne

Subjects
Aged Health Care, Neurology and Neuromuscular Diseases, FOS: Clinical medicine
Abstract

Supplemental material, sj-docx-1-msj-10.1177_13524585231181578 for Association between clinic-level quality of care and patient-level outcomes in multiple sclerosis by Anna H He, Ali Manouchehrinia, Anna Glaser, Olga Ciccarelli, Helmut Butzkueven, Jan Hillert and Kyla Anne McKay in Multiple Sclerosis Journal

Published
2023
Full Text
View/download PDF

18. sj-pdf-2-mso-10.1177_20552173231153557 - Supplemental material for Proportion and characteristics of secondary progressive multiple sclerosis in five European registries using objective classifiers

Author

Forsberg, Lars, Spelman, Tim, Klyve, Pernilla, Manouchehrinia, Ali, Ramanujam, Ryan, Mouresan, Elena, Drahota, Jiri, Horakova, Dana, Joensen, Hanna, Pontieri, Luigi, Magyari, Melinda, Ellenberger, David, Stahmann, Alexander, Rodgers, Jeff, Witts, James, Middleton, Rod, Nicholas, Richard, Bezlyak, Vladimir, Adlard, Nicholas, Hach, Thomas, Lines, Carol, Vukusic, Sandra, Soilu-Hänninen, Merja, van der Walt, Anneke, Butzkueven, Helmut, Iaffaldano, Pietro, Trojano, Maria, Glaser, Anna, and Hillert, Jan

Subjects
FOS: Clinical medicine, 110904 Neurology and Neuromuscular Diseases, Neuroscience
Abstract

Supplemental material, sj-pdf-2-mso-10.1177_20552173231153557 for Proportion and characteristics of secondary progressive multiple sclerosis in five European registries using objective classifiers by Lars Forsberg, Tim Spelman, Pernilla Klyve, Ali Manouchehrinia, Ryan Ramanujam, Elena Mouresan, Jiri Drahota, Dana Horakova, Hanna Joensen, Luigi Pontieri, Melinda Magyari, David Ellenberger, Alexander Stahmann, Jeff Rodgers, James Witts, Rod Middleton, Richard Nicholas, Vladimir Bezlyak, Nicholas Adlard, Thomas Hach, Carol Lines, Sandra Vukusic, Merja Soilu-Hänninen, Anneke van der Walt, Helmut Butzkueven, Pietro Iaffaldano, Maria Trojano, Anna Glaser, Jan Hillert and in Multiple Sclerosis Journal – Experimental, Translational and Clinical

Published
2023
Full Text
View/download PDF

19. sj-docx-1-mso-10.1177_20552173231153557 - Supplemental material for Proportion and characteristics of secondary progressive multiple sclerosis in five European registries using objective classifiers

Author

Forsberg, Lars, Spelman, Tim, Klyve, Pernilla, Manouchehrinia, Ali, Ramanujam, Ryan, Mouresan, Elena, Drahota, Jiri, Horakova, Dana, Joensen, Hanna, Pontieri, Luigi, Magyari, Melinda, Ellenberger, David, Stahmann, Alexander, Rodgers, Jeff, Witts, James, Middleton, Rod, Nicholas, Richard, Bezlyak, Vladimir, Adlard, Nicholas, Hach, Thomas, Lines, Carol, Vukusic, Sandra, Soilu-Hänninen, Merja, van der Walt, Anneke, Butzkueven, Helmut, Iaffaldano, Pietro, Trojano, Maria, Glaser, Anna, and Hillert, Jan

Subjects
FOS: Clinical medicine, 110904 Neurology and Neuromuscular Diseases, Neuroscience
Abstract

Supplemental material, sj-docx-1-mso-10.1177_20552173231153557 for Proportion and characteristics of secondary progressive multiple sclerosis in five European registries using objective classifiers by Lars Forsberg, Tim Spelman, Pernilla Klyve, Ali Manouchehrinia, Ryan Ramanujam, Elena Mouresan, Jiri Drahota, Dana Horakova, Hanna Joensen, Luigi Pontieri, Melinda Magyari, David Ellenberger, Alexander Stahmann, Jeff Rodgers, James Witts, Rod Middleton, Richard Nicholas, Vladimir Bezlyak, Nicholas Adlard, Thomas Hach, Carol Lines, Sandra Vukusic, Merja Soilu-Hänninen, Anneke van der Walt, Helmut Butzkueven, Pietro Iaffaldano, Maria Trojano, Anna Glaser, Jan Hillert and in Multiple Sclerosis Journal – Experimental, Translational and Clinical

Published
2023
Full Text
View/download PDF

26. 1298Associations of DMT therapies with COVID-19 severity in multiple sclerosis

Author

Simpson-Yap, Steve, primary, Brouwer, Edward De, additional, Kalincik, Tomas, additional, Rijke, Nick, additional, Hillert, Jan, additional, Walton, Clare, additional, Edan, Gilles, additional, Spelman, Tim, additional, Geyes, Lotte, additional, Parciak, Tina, additional, Gautrais, Clément, additional, Lazovski, Nikola, additional, Pirmani, Ashkan, additional, Ardeshirdavani, Amin, additional, Forsberg, Lars, additional, Glaser, Anna, additional, McBurney, Robert, additional, Schmidt, Hollie, additional, Bergmann, Arnfin, additional, Braune, Stefan, additional, Stahmann, Alexander, additional, Middleton, Rodden, additional, Salter, Amber, additional, Fox, Robert, additional, van der Walt, Anneke, additional, Butzkueven, Helmut, additional, Rojas, Juan, additional, van der Mei, Ingrid, additional, Nag, Nupur, additional, Ivanov, Rumen, additional, Olival, Guilherme Sciascia do, additional, Dias, Alice Estavo, additional, Magyari, Melinda, additional, Brum, Doralina Guimarães, additional, Mendes, Maria Fernandes, additional, Alonso, Ricardo, additional, Nicholas, Richard, additional, Bauer, Johana, additional, Chertcoff, Anibal, additional, Zabalza, Ana, additional, Arrambide, Georgina, additional, Fidao, Alexander, additional, Comi, Giancarlo, additional, and Peeters, Liesbet, additional

Published
2021
Full Text
View/download PDF

27. A rare P2X7 variant Arg307Gln with absent pore formation function protects against neuroinflammation in multiple sclerosis

Author

Gu, Ben J., Field, Judith, Dutertre, Sébastien, Ou, Amber, Kilpatrick, Trevor J., Lechner-Scott, Jeannette, Scott, Rodney, Lea, Rodney, Taylor, Bruce V., Stankovich, Jim, Butzkueven, Helmut, Gresle, Melissa, Laws, Simon M., Petrou, Steven, Hoffjan, Sabine, Akkad, Denis A., Graham, Colin A., Hawkins, Stanley, Glaser, Anna, Bedri, Sahl Khalid, Hillert, Jan, Matute, Carlos, Antiguedad, Alfredo, Wiley, James S., Baxter, Alan G., Kermode, Allan G., Taylor, Bruce V., Booth, David R., Mason, Deborah F., Stewart, Graeme J., Butzkueven, Helmut, Charlesworth, Jac C., Wiley, James S., Lechner-Scott, Jeannette S., Field, Judith, Tajouri, Lotti, Griffiths, Lyn R., Slee, Mark, Brown, Matthew A., Moscato, Pablo, Scott, Rodney J., Broadley, Simon A., Vucic, Steve, Kilpatrick, Trevor J., Carroll, William M., and Barnett, Michael H.

Published
2015
Full Text
View/download PDF

29. Cosmic Order and Divine Power

Author

Burri, Renate, primary, Chandler, Clive, additional, Daiber, Hans, additional, Kraye, Jill, additional, Smith, Andrew, additional, Takahashi, Hidemi, additional, and Tzvetkova-Glaser, Anna, additional

Published
2014
Full Text
View/download PDF

32. sj-pdf-3-msj-10.1177_13524585211019649 – Supplemental material for A comparative study of teriflunomide and dimethyl fumarate within the Swedish MS Registry

Author

Hillert, Jan, Tsai, Jon A, Nouhi, Mona, Glaser, Anna, and Spelman, Tim

Subjects
FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 110904 Neurology and Neuromuscular Diseases
Abstract

Supplemental material, sj-pdf-3-msj-10.1177_13524585211019649 for A comparative study of teriflunomide and dimethyl fumarate within the Swedish MS Registry by Jan Hillert, Jon A Tsai, Mona Nouhi, Anna Glaser and Tim Spelman in Multiple Sclerosis Journal

Published
2021
Full Text
View/download PDF

33. sj-pdf-1-msj-10.1177_13524585211019649 – Supplemental material for A comparative study of teriflunomide and dimethyl fumarate within the Swedish MS Registry

Author

Hillert, Jan, Tsai, Jon A, Nouhi, Mona, Glaser, Anna, and Spelman, Tim

Subjects
FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 110904 Neurology and Neuromuscular Diseases
Abstract

Supplemental material, sj-pdf-1-msj-10.1177_13524585211019649 for A comparative study of teriflunomide and dimethyl fumarate within the Swedish MS Registry by Jan Hillert, Jon A Tsai, Mona Nouhi, Anna Glaser and Tim Spelman in Multiple Sclerosis Journal

Published
2021
Full Text
View/download PDF

34. sj-pdf-2-msj-10.1177_13524585211019649 – Supplemental material for A comparative study of teriflunomide and dimethyl fumarate within the Swedish MS Registry

Author

Hillert, Jan, Tsai, Jon A, Nouhi, Mona, Glaser, Anna, and Spelman, Tim

Subjects
FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 110904 Neurology and Neuromuscular Diseases
Abstract

Supplemental material, sj-pdf-2-msj-10.1177_13524585211019649 for A comparative study of teriflunomide and dimethyl fumarate within the Swedish MS Registry by Jan Hillert, Jon A Tsai, Mona Nouhi, Anna Glaser and Tim Spelman in Multiple Sclerosis Journal

Published
2021
Full Text
View/download PDF

35. Objective classification of multiple sclerosis disease course results in frequent reclassification to secondary progressive multiple sclerosis

Author

Hillert, Jan, Forsberg, Lars, Manouchehrinia, Ali, Ramanujam, Ryan, Spelman, Timothy, Klyve, Pernilla, Drahota, Jiri, Horakova, Dana, Joensen, Hanna, Magyari, Melinda, Ellenberger, David, Stahmann, Alexander, Van der Walt, Anneke, Rodgers, Jeff, Witts, James A., Middleton, Rod, Nicholas, Richard, Bezlyak, Vladimir, Adlard, Nicholas, Hach, Thomas, Lines, Carol, Glaser, Anna, Hillert, Jan, Forsberg, Lars, Manouchehrinia, Ali, Ramanujam, Ryan, Spelman, Timothy, Klyve, Pernilla, Drahota, Jiri, Horakova, Dana, Joensen, Hanna, Magyari, Melinda, Ellenberger, David, Stahmann, Alexander, Van der Walt, Anneke, Rodgers, Jeff, Witts, James A., Middleton, Rod, Nicholas, Richard, Bezlyak, Vladimir, Adlard, Nicholas, Hach, Thomas, Lines, Carol, and Glaser, Anna

Abstract

QC 20220120

Published
2021

38. Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: A study of the Swedish multiple sclerosis registry.

Author

Spelman, Tim, Forsberg, Lars, McKay, Kyla, Glaser, Anna, and Hillert, Jan

Subjects
MULTIPLE sclerosis, COVID-19, COVID-19 pandemic, HOSPITAL care, ODDS ratio
Abstract

Background: The primary objective of this study was to analyse the association between multiple sclerosis (MS) disease-modifying therapy (DMT) exposure and hospitalisation in patients infected with COVID-19. Methods: Associations between MS DMT exposure and COVID-19 hospitalisation were analysed using univariable and multi-variable-clustered propensity score weighted logistic regression, where the models were clustered on the individual patients to control for patients contributing multiple COVID-19 episodes. Findings: As of 18 January 2021, a total of 476 reported COVID-19 cases had been recorded in MS patients in the Swedish MS registry. Of these, 292 (61.3%) had confirmed COVID-19. The mean value (standard deviation (SD)) age at infection was 44.0 years (11.6). Of the 292 confirmed infections, 68 (23.2%) required hospitalisation. A total of 49 of the 164 confirmed COVID-19 patients on rituximab at baseline (29.9%) required hospitalisation, compared to a rate of 12.7% for all other DMTs combined. Rituximab in confirmed COVID-19 patients was associated with 2.95 times the odds of hospitalisation relative to any other DMT combined (odds ratio = 2.95; 95% confidence interval (CI) = 1.48–5.87). Interpretation: Rituximab treatment, known to increase the risk of severe infections in general, also confers such a risk for MS patients with COVID-19, in comparison with other MS DMTs. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

39. Objective classification of multiple sclerosis disease course results in frequent reclassification to secondary progressive multiple sclerosis (4094)

Author

Hillert, Jan, primary, Forsberg, Lars, additional, Manouchehrinia, Ali, additional, Ramanujam, Ryan, additional, Spelman, Timothy, additional, Klyve, Pernilla, additional, Drahota, Jiri, additional, Horakova, Dana, additional, Joensen, Hanna, additional, Magyari, Melinda, additional, Ellenberger, David, additional, Stahmann, Alexander, additional, Van Der Walt, Anneke, additional, Rodgers, Jeff, additional, Witts, James A., additional, Middleton, Rod, additional, Nicholas, Richard, additional, Bezlyak, Vladimir, additional, Adlard, Nicholas, additional, Hach, Thomas, additional, Lines, Carol, additional, and Glaser, Anna, additional

Published
2021
Full Text
View/download PDF

42. Associations of DMT therapies with COVID-19 severity in multiple sclerosis

Author

Simpson-Yap, Steve, primary, De Brouwer, Edward, additional, Kalincik, Tomas, additional, Rijke, Nick, additional, Hillert, Jan, additional, Walton, Clare, additional, Edan, Gilles, additional, Moreau, Yves, additional, Spelman, Tim, additional, Geys, Lotte, additional, Parciak, Tina, additional, Gautrais, Clément, additional, Lazovski, Nikola, additional, Pirmani, Ashkan, additional, Ardeshirdavani, Amin, additional, Forsberg, Lars, additional, Glaser, Anna, additional, McBurney, Robert, additional, Schmidt, Hollie, additional, Bergmann, Arnfin, additional, Braune, Stefan, additional, Stahmann, Alexander, additional, Middleton, Rodden, additional, Salter, Amber, additional, Fox, Robert J., additional, van der Walt, Anneke, additional, Butzkueven, Helmut, additional, Al-Roughani, Raed, additional, Ozakbas, Serkan, additional, Rojas, Juan I, additional, van der Mei, Ingrid, additional, Nag, Nupur, additional, Ivanov, Rumen, additional, do Olival, Guilherme Sciascia, additional, Dias, Alice Estavo, additional, Magyari, Melinda, additional, Guimarães Brum, Doralina, additional, Mendes, Maria Fernanda, additional, Alonso, Ricardo, additional, Nicholas, Richard, additional, Bauer, Johana, additional, Chertcoff, Anibal, additional, Zabalza, Ana, additional, Arrambide, Georgina, additional, Fidao, Alexander, additional, Comi, Giancarlo, additional, and Peeters, Liesbet M., additional

Published
2021
Full Text
View/download PDF

43. Association study of cholesterol-related genes in Alzheimer’s disease

Author

Wollmer, M. Axel, Sleegers, Kristel, Ingelsson, Martin, Zekanowski, Cezary, Brouwers, Nathalie, Maruszak, Aleksandra, Brunner, Fabienne, Huynh, Kim-Dung, Kilander, Lena, Brundin, Rose-Marie, Hedlund, Marie, Giedraitis, Vilmantas, Glaser, Anna, Engelborghs, Sebastiaan, De Deyn, Peter P., Kapaki, Elisabeth, Tsolaki, Magdalini, Daniilidou, Makrina, Molyva, Dimitra, Paraskevas, George P., Thal, Dietmar R., Barcikowska, Maria, Kuznicki, Jacek, Lannfelt, Lars, Van Broeckhoven, Christine, Nitsch, Roger M., Hock, Christoph, and Papassotiropoulos, Andreas

Published
2007
Full Text
View/download PDF

45. A comparative study of teriflunomide and dimethyl fumarate within the Swedish MS Registry.

Author

Hillert, Jan, Tsai, Jon A, Nouhi, Mona, Glaser, Anna, and Spelman, Tim

Subjects
DIMETHYL fumarate, TERMINATION of treatment, PROPENSITY score matching, MULTIPLE sclerosis, COMPARATIVE studies
Abstract

Background: Teriflunomide and dimethyl fumarate (DMF) are first-line disease-modifying treatments for multiple sclerosis with similar labels that are used in comparable populations. Objectives: The objective of this study was to compare the effectiveness and persistence of teriflunomide and DMF in a Swedish real-world setting. Methods: All relapsing-remitting multiple sclerosis (RRMS) patients in the Swedish MS registry initiating teriflunomide or DMF were included in the analysis. The primary endpoint was treatment persistence. Propensity score matching was used to adjust comparisons for baseline confounders. Results: A total of 353 teriflunomide patients were successfully matched to 353 DMF. There was no difference in the rate of overall treatment discontinuation by treatment group across the entire observation period (hazard ratio (HR) = 1.12; 95% confidence interval (CI) = 0.91–1.39; p = 0.277; reference = teriflunomide). Annualised relapse rate (ARR) was comparable (p = 0.237) between DMF (0.07; 95% CI = 0.05–0.10) and teriflunomide (0.09; 95% CI = 0.07–0.12). There was no difference in time to first on-treatment relapse (HR = 0.78; 95% CI = 0.50–1.21), disability progression (HR = 0.55; 95% CI = 0.27–1.12) or confirmed improvement (HR = 1.17; 95% CI = 0.57–2.36). Conclusion: This population-based real-world study reports similarities in treatment persistence, clinical effectiveness and quality of life outcomes between teriflunomide and dimethyl fumarate. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

47. Comparison of the proportions of Secondary Progressive Multiple Sclerosis between three registries within the SPMS Research Collaboration Network (3977)

Author

Forsberg, Lars, primary, Stahmann, Alexander, additional, Middleton, Rod, additional, Ellenberger, David, additional, Rodgers, Jeff, additional, Nicholas, Richard, additional, Ramanujam, Ryan, additional, Manouchehrinia, Ali, additional, Pillai, Natasha, additional, Dobay, Pamela, additional, Lines, Carol, additional, Hach, Thomas, additional, Glaser, Anna, additional, and Hillert, Jan, additional

Published
2020
Full Text
View/download PDF

48. Associations of DMT Therapies with COVID-19 Severity in Multiple Sclerosis: An International Cohort Study

Author

Simpson-Yap, Steve, primary, De Brouwer, Edward, additional, Kalincik, Tomas, additional, Rijke, Nick, additional, Hillert, Jan, additional, Walton, Clare, additional, Edan, Gilles, additional, Moreau, Yves, additional, Spelman, Tim, additional, Geys, Lotte, additional, Parciak, Tina, additional, Gautrais, Clément, additional, Lazovski, Nikola, additional, Pirmani, Ashkan, additional, Ardeshirdavani, Amin, additional, Forsberg, Lars, additional, Glaser, Anna, additional, McBurney, Robert, additional, Schmidt, Hollie, additional, Bergmann, Arnfin, additional, Braune, Stefan, additional, Stahmann, Alexander, additional, Middleton, Rodden, additional, Salter, Amber, additional, Fox, Robert J., additional, Van Der Welt, Anneke, additional, Butzkueven, Helmut, additional, Rojas, Juan I., additional, van der Mei, Ingrid, additional, Nag, Nupur, additional, Ivanov, Rumen, additional, Sciascia do Olival, Guilherme, additional, Estevo Dias, Alice, additional, Magyari, Melinda, additional, Brum, Doralina Guimarães, additional, Mendes, Maria Fernanda, additional, Alonso, Ricardo, additional, Nicholas, Richard, additional, Bauer, Johana, additional, Chertcoff, Anibal, additional, Zabalza, Ana, additional, Arrambide, Georgina, additional, Fidao, Alexander, additional, Comi, Giancarlo, additional, and Peeters, Liesbet M., additional

Published
2020
Full Text
View/download PDF

50. Editorial : Hackathons & Co : entre fascination et rejet

Author

Fabbri, Julie, Toutain, Olivier, Glaser, Anna, emlyon business school, and business school, emlyon

Subjects
maker, hackathon, [SHS.GESTION]Humanities and Social Sciences/Business administration, evenement, innovation challenge, [SHS.ECO] Humanities and Social Sciences/Economics and Finance, [SHS.GESTION] Humanities and Social Sciences/Business administration, meet up, [SHS.ECO]Humanities and Social Sciences/Economics and Finance, startup week-end, design sprint, Événements Collaboratifs d’Innovation
Abstract

International audience; Les « hackathons » et autres « startup weekends » ou encore « innovation challenges » sont à la mode ; cela n’aura échappé à personne. Ces Événements Collaboratifs d’Innovation (ECI) ou « événements makers » rassemblent des publics différents (des spécialistes aux personnes les moins averties), sous des formats variés en termes de taille (depuis la réunion d’une poignée de « makers » jusqu’aux grands-messes type « Maker Faires ») et à des niveaux d’implication divers (simples observateurs, participants, organisateurs...).

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results